Dudediligence.

ImmunityBio, Inc

IBRXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$6.1MSep ’24$7.6MDec ’24$16.5MMar ’25$26.4MJun ’25$32.1MSep ’25$38.3MDec ’25$44.2MMar ’26$51.2MJun ’26
Net income, by quarter
−$85.7MSep ’24−$59.2MDec ’24−$129.6MMar ’25−$92.6MJun ’25−$67.3MSep ’25−$62.0MDec ’25−$632.8MMar ’26−$230.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$934,000$240,000$622,000$14.7M$113.3M
Gross profitnone on file$240,000$622,000$14.7M$112.5M
Operating income−$330.3M−$351.3M−$362.3M−$344.2M−$256.0M
Net income−$346.8M−$416.6M−$583.2M−$413.6M−$351.5M
Operating cash flow−$274.4M−$337.5M−$366.8M−$391.2M−$304.9M
Free cash flow−$308.0M−$415.7M−$397.3M−$398.1M−$308.8M
Cash$181.1M$104.6M$265.5M$143.4M$88.3M
Debtnone on filenone on filenone on file$1.2Mnone on file
Shares outstanding397.8M421.6M670.9M852.9M1.01B